UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. パーキンソン病の初期薬物療法initial pharmacologic treatment of parkinson disease [show details]
…compared with levodopa alone. The STRIDE-PD trial randomly assigned 747 patients with early PD to levodopa-carbidopa alone or combined with entacapone . Patients assigned to combined therapy with entacapone had …
2. パーキンソン病のデバイス補助療法と手術療法device assisted and surgical treatments for parkinson disease [show details]
…between the DBS pulse generator and the cardiac pacemaker. Carbidopa-levodopa enteral suspension, commonly known as levodopa-carbidopa intestinal gel (LCIG), is approved by the US Food and Drug Administration …
3. パーキンソン病の運動症状の日内変動とジスキネジアの医療管理medical management of motor fluctuations and dyskinesia in parkinson disease [show details]
…further improved by medical therapy. These treatments (deep brain stimulation [DBS], continuous levodopa-carbidopa intestinal gel [LCIG] infusion, and continuous subcutaneous apomorphine infusion [CSAI]) are …
4. パーキンソン病への新たな疾患修飾療法potential disease modifying therapies for parkinson disease [show details]
…assigned 445 patients with early PD to receive carbidopa-levodopa for 80 weeks (early-start group) or placebo for 40 weeks followed by carbidopa-levodopa for 40 weeks (delayed-start group) . At 80 weeks …
5. パーキンソン病の診断および鑑別診断diagnosis and differential diagnosis of parkinson disease [show details]
…parkinsonian symptoms using the part III motor score before and after a dose of levodopa (eg, carbidopa-levodopa 25/250 mg) or subcutaneous apomorphine (1.5 to 4.5 mg). Although there is no standard definition…

Japanese Journal

第一原理計算によるカルコパイライト磁性半導体薄膜の熱電物性

高木博和,小林一昭,下野昌人,小林伸彦,広瀬賢二,辻井直人,森孝雄
日本物理学会講演概要集 72.1(0), 2527-2527, 2017
… <p>カルコパイライト型磁性半導体であるCuFeS_2_は室温近傍で!LaTeX$500~{\mu V/K}$程の大きなSeebeck係数を取り、さらにドーピングによるパワーファクターの増強が可能であることが報告されており、近年では有用な熱電材料の一つとして精力的な研究がなされている。 …
NAID 130006710368